What is Arbutus Biopharma Corporation's long-term debt?

Arbutus Biopharma Corporation (ABUS) reported long-term debt of $0 in Q1 2026.

What does long-term debt mean?

Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.

Arbutus Biopharma Corporation ABUS Long-Term Debt

Long-Term Debt at other companies

Gilead SciencesGILD

$20.86B-5.8%

ImmunityBio, Inc.IBRX

$404.3M+36.5%

Lantheus HoldingsLNTH

$570.41M+0.6%

Beam TherapeuticsBEAM

$100.19M—

BioCryst PharmaceuticalsBCRX

$395.2M+25.3%

CRISPR TherapeuticsCRSP

$585.47M—

Other financials

Income statement

See full

Revenue$179.1M+10,055%

Operating income$168.9M+757%

Net income$169.7M+792%

EPS (diluted)$0.87+769%

Balance sheet

See full

Cash & equivalents$23.7M-36.1%

Total debt$631.0K-46.9%

Total equity$260.2M+229%

Total assets$277.2M+137%

Cash flow

See full

Operating cash flow-$8.1M+39.4%

CapEx--100%

Free cash flow-$4.7M+55.0%

Valuation

See full

Market cap$881.02M+34.1%

Enterprise value$857.94M+38.1%

P/E5.5×—

P/S4.6×-98.0×

Profitability

See full

Operating margin81.7%+42.1pp

Net margin84%+43.4pp

FCF margin-281.5%-119pp

Returns & leverage

See full

Return on equity94.7%+65.1pp

Debt / equity0×0.0×

Current ratio54.3×+48.3×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebt.

The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arbutus Biopharma Corporation's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arbutus Biopharma Corporation's long-term debt?: Arbutus Biopharma Corporation (ABUS) reported long-term debt of $0 in Q1 2026.
What does long-term debt mean?: Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.